Common Contracts
3 similar Global License Agreement contracts by Theravance Biopharma, Inc.
ContractGlobal License Agreement • December 4th, 2022
Theravance Biopharma and Pfizer Inc. Enter Global License Agreement for Skin-Targeted, Locally-Acting Pan-Janus Kinase (JAK) Inhibitor Program
ContractGlobal License Agreement • December 4th, 2022
Theravance Biopharma and Pfizer Inc. Enter Global License Agreement for Skin-Targeted, Locally-Acting Pan-Janus Kinase (JAK) Inhibitor Program
Theravance Biopharma and Pfizer Inc. Enter Global License Agreement for Skin- Targeted, Locally-Acting Pan-Janus Kinase (JAK) Inhibitor ProgramGlobal License Agreement • December 26th, 2019 • Theravance Biopharma, Inc. • Pharmaceutical preparations
Dublin, Ireland and New York – December 23, 2019 – Theravance Biopharma Ireland Limited, a subsidiary of Theravance Biopharma, Inc. (NASDAQ: TBPH) (“Theravance Biopharma”) and Pfizer Inc. (NYSE: PFE) (“Pfizer”) today announced that the companies have entered into a global license agreement for Theravance Biopharma’s preclinical program for skin-targeted, locally-acting pan-Janus kinase (JAK) inhibitors that can be rapidly metabolized. The compounds in this program target validated pro-inflammatory pathways and are specifically designed to possess skin-selective activity with minimal systemic exposure.
